ADA: AstraZeneca's diabetes-fighter Farxiga cuts risk of fast decline in kidney function
Novo Nordisk Snags FDA Approval for Oral Type 2 Diabetes Drug
J&J's Invokana closes in on badly needed kidney disease nod with FDA 'priority' boost
Novo’s next big diabetes bet heads to regulators
Johnson & Johnson bags long-awaited cardiovascular nod for diabetes drug Invokana
Pharma TV buys so far top last year's $1B spend; AbbVie, Pfizer lead September
AstraZeneca diabetes drug cuts heart risks in major study
Dive Brief: Against a backdrop of intense market competition, Novo Nordisk has rolled out a direct-to-consumer campaign for Ozempic, its once-weekly, injectable Type 2 diabetes medication. Set to the tune of Pilot's 1974 hit "Magic," the 90-second spot touts that a majority of adults in a study of the drug achieved lower blood sugar and … Συνεχίστε να διαβάζετε With diabetes competitive as ever, Novo launches Ozempic DTC campaign.
What Did Ian Read Learn From Trump? Pfizer Inc. CEO Ian Read may have as much insight as anyone in the pharma world into US President Donald Trump's thinking on drug pricing and potential policy steps, after talking to the president on the phone and visiting him at the White House in July. You can bet … Συνεχίστε να διαβάζετε Pharma Q2 Results Preview: Pfizer, Teva, Shire, Sanofi And Novo Nordisk.
Johnson & Johnson's second quarter earnings, released on Tuesday, largely beat analysts' expectations, thanks in part to growth in autoimmune drugs, particularly by the Crohn's disease medication Stelara. Worldwide sales of Stelara were up 36.4% in Q2 to $1.3 billion worldwide. The company's worldwide pharma sales increased by 19.9% from the year prior … Συνεχίστε να διαβάζετε Stelara highlights J&J’s Q2 performance.